Merck KGaA (OTCMKTS:MKGAF) Stock Price Up 10.2% - What's Next?

Key Points

• Merck KGaA shares surged 10.2% on Tuesday to $142.5530, with trading peaking at $142.5530 on unusually light volume of about 192 shares (down ~67% from the average 583).
• The company has a market capitalization of $18.42 billion, a P/E of 21.76, debt/equity of 0.27 and a current ratio of 1.31, while the 50‑day and 200‑day simple moving averages are $137.77 and $139.62 respectively.
• Merck KGaA is a long-established, family-controlled German multinational in chemicals and pharmaceuticals, operating across three main business units and serving global markets.

Merck KGaA (OTCMKTS:MKGAF - Get Free Report) rose 10.2% during trading on Tuesday . The company traded as high as $142.5530 and last traded at $142.5530. Approximately 192 shares changed hands during trading, a decline of 67% from the average daily volume of 583 shares. The stock had previously closed at $129.3370.

Merck KGaA Price Performance

The stock has a market capitalization of $18.42 billion, a price-to-earnings ratio of 21.76 and a beta of 0.96. The company has a current ratio of 1.31, a quick ratio of 0.84 and a debt-to-equity ratio of 0.27. The stock has a 50-day simple moving average of $137.77 and a 200 day simple moving average of $139.62.

Merck KGaA Company Profile

Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.

The company's operations are organized mainly into three businesses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.